ORIGIN - Sökresultat

Australien - engelska - Department of Health (Therapeutic Goods Administration)

comirnaty original/omicron ba.4-5 (tozinameran/famtozinameran) covid-19 vaccine 15/15 micrograms/0.3 ml suspension for injection vial

pfizer australia pty ltd - tozinameran, quantity: 50 microgram/ml; famtozinameran, quantity: 50 microgram/ml - injection, suspension - excipient ingredients: cholesterol; sucrose; distearoylphosphatidylcholine; ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); 2-((polyethylene glycol)-2000)-n-n-ditetradecylacetamide; trometamol hydrochloride; water for injections; trometamol - comirnaty original/omicron ba.4-5 vaccine has provisional approval for the indication below:,active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov- 2, in individuals12 years of age and older.,the use of this vaccine should be in accordance with official recommendations.,the decision has been made on the basis of short term immunogenicity and safety data. continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment.

Israel - engelska - Ministry of Health

baclofen sintetica 2 mg ml

cts ltd - baclofen - solution for infusion - baclofen 2 mg/ml - baclofen - baclofen sintetica is indicated in patients with severe chronic spasticity resulting from trauma, multiple sclerosis or other spinal cord disorders, who are unresponsive to oral baclofen or other orally administered antispastic agents and/or those patients who experience unacceptable side effects at effective oral doses.baclofen sintetica is effective in adult patients with severe chronic spasticity of cerebral origin, resulting e.g. from cerebral palsy, brain trauma or cerebrovascular accident; however, clinical experience is limited.paediatric population: baclofen sintetica indicated in patients aged 4 to <18 years with severe chronic spasticity of cerebral origin or of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Israel - engelska - Ministry of Health

baclofen sintetica 0.5 mgml

cts ltd - baclofen - solution for infusion - baclofen 0.5 mg / 1 ml - baclofen - baclofen sintetica is indicated in patients with severe chronic spasticity resulting from trauma, multiple sclerosis or other spinal cord disorders, who are unresponsive to oral baclofen or other orally administered antispastic agents and/or those patients who experience unacceptable side effects at effective oral doses.baclofen sintetica is effective in adult patients with severe chronic spasticity of cerebral origin, resulting e.g. from cerebral palsy, brain trauma or cerebrovascular accident; however, clinical experience is limited.paediatric population: baclofen sintetica indicated in patients aged 4 to <18 years with severe chronic spasticity of cerebral origin or of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

USA - engelska - NLM (National Library of Medicine)

careone milk of magnesia original milk of magnesia original- magnesium hydroxide liquid

retail business services, llc. - magnesium hydroxide (unii: nbz3qy004s) (magnesium cation - unii:t6v3lhy838) - saline laxative relieves occasional constipation (irregularity). this product usually produces bowel movement in 1/2 to 6 hours. - kidney disease - a magnesium-restricted diet - stomach pain, nausea, or vomiting - a sudden change in bowel habits that lasts over 14 days taking a prescription drug. this product may interact with certain prescription drugs. - you have rectal bleeding or no bowel movement after using this product. these could be signs of a serious condition. - you need to use a laxative for more than 1 week